Indiana University School Of Medicine

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1903-01-01

Employees: -

Market Cap: -

Website: http://www.medicine.iu.edu

Clinical Trials

Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma

Phase 1

Terminated

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Lenalidomide
Drug: Sorafenib

First Posted Date: 2011-05-05

Last Posted Date: 2015-08-31

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 5

Registration Number: NCT01348503

Locations: 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

Does Inspection During Insertion Improve Adenoma Yields During Colonoscopy?

Not Applicable

Completed

Conditions: Colorectal Cancer
Colorectal Polyps

Interventions: Procedure: Inspection during insertion
Procedure: Inspection during withdrawal

First Posted Date: 2009-12-21

Last Posted Date: 2018-11-16

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 340

Registration Number: NCT01035775

Locations: 🇺🇸
Beltway Surgery Center, Indianapolis, Indiana, United States
🇺🇸
Indiana University Hospital, Indianapolis, Indiana, United States

Brain Imaging of Quetiapine Response in Anxious Depression

Phase 4

Completed

Conditions: Major Depression

Interventions: Drug: quetiapine (Seroquel XR)

First Posted Date: 2009-09-23

Last Posted Date: 2016-09-30

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 20

Registration Number: NCT00982345

Locations: 🇺🇸
Indiana University Adult Psychiatry Clinic, Indianapolis, Indiana, United States

Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)

Not Applicable

Terminated

Conditions: Coronary Artery Disease

Interventions: Drug: Atorvastatin

First Posted Date: 2009-09-18

Last Posted Date: 2015-09-22

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 60

Registration Number: NCT00979940

Locations: 🇺🇸
Methodist Hospital, Indianapolis, Indiana, United States
🇺🇸
Wishard Hospital, Indianapolis, Indiana, United States

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

Phase 2

Completed

Conditions: Myelofibrosis
Anemia, Aplastic
Hemoglobinuria, Paroxysmal
Acute Myelogenous Leukemia
Acute Lymphocytic Leukemia
Chronic Myelogenous Leukemia
Chronic Lymphocytic Leukemia
Myelodysplasia
Non-Hodgkin's Lymphoma
Hodgkin's Disease

Interventions: Drug: Basiliximab

First Posted Date: 2009-09-14

Last Posted Date: 2016-02-26

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 17

Registration Number: NCT00975975

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute
Leukemia, Promyelocytic, Acute
Myelodysplastic Syndromes

Interventions: Drug: Sorafenib-Vorinostat

First Posted Date: 2009-04-03

Last Posted Date: 2014-09-18

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 15

Registration Number: NCT00875745

Locations: 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

Sitagliptin Umbilical Cord Blood Transplant Study

Phase 2

Completed

Conditions: Myelodysplasia
Leukemia, Myelogenous, Chronic
Lymphoma, Non-Hodgkin
Leukemia, Myeloid, Acute
Acute Lymphoblastic Leukemia

Interventions: Drug: Sitagliptin

First Posted Date: 2009-03-17

Last Posted Date: 2016-10-07

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 29

Registration Number: NCT00862719

Locations: 🇺🇸
IU Simon Cancer Center, Indianapolis, Indiana, United States

Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasm Metastasis
Carcinoma

Interventions: Drug: Paclitaxel plus PTK787

First Posted Date: 2008-08-11

Last Posted Date: 2014-09-11

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 28

Registration Number: NCT00731861

Locations: 🇺🇸
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States

In-Vitro Studies in Depletion of Haplotype Mismatched Alloreactive T Cells

Withdrawn

Conditions: Hematologic Malignancies
Hematopoietic Stem Cell Transplantation

Interventions: Procedure: collection of peripheral blood and apheresis samples

First Posted Date: 2008-08-11

Last Posted Date: 2014-09-19

Lead Sponsor: Indiana University School of Medicine

Registration Number: NCT00731705

Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram

Phase 4

Completed

Conditions: Major Depression

Interventions: Drug: Escitalopram

First Posted Date: 2008-07-01

Last Posted Date: 2016-10-17

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 17

Registration Number: NCT00707863

Locations: 🇺🇸
Indiana University Adult Psychiatric Clinic, Indianapolis, Indiana, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy